Unsaturated Carbocyclic Ring Or Acyclic Carbon To Carbon Unsaturation Containing Patents (Class 549/77)
-
Publication number: 20110105572Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is a C5-20heteroaryl or C5-20carboaryl group and is optionally substituted; Q1 is a C2-7alkylene group having a backbone of at least 2 carbon atoms, and is optionally substituted; J is —N(R1)C(?O)— or —C(?O)N(R1)—; R1 is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q2 is C1-7alkylene, C5-20arylene, C5-20arylene-C1-7alkylene, or C1-7alkylene-C5-20arylene having a backbone of at least 3 carbon atoms, and is optionally substituted; and pharmaceutically acceptable salts thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to treat proliferative conditions, such as cancer and psoriasis.Type: ApplicationFiled: January 4, 2011Publication date: May 5, 2011Inventors: Clare J. Watkins, Maria Rosario Romero-Martin, Kathryn G. Moore, James Ritchie, Paul W. Finn, Ivars Kalvinsh, Einars Loza, Igor Starchenkov, Klara Dikovska, Rasma M. Bokaldere, Vija Gailite, Maxim Vorona, Victor Andrianov, Daina Lolya, Valentina Semenikhina, Andris Amolins, C. John Harris, James E.S. Duffy
-
Publication number: 20110104162Abstract: The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and especially to a racemic mixture. The present invention also relates to the use of these compounds as a medicament, and in particular for the treatment of cancer, and also to the compositions containing them.Type: ApplicationFiled: June 15, 2009Publication date: May 5, 2011Applicant: Cytomics SystemsInventors: Denis Carniato, Karine Jaillardon, Olivier Busnel, Mathieu Gutmann, Jean-Francois Briand, Benoit Deprez, Dominique Thomas, Cécile Bougeret
-
Publication number: 20110106241Abstract: Amidine analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumor cells.Type: ApplicationFiled: October 2, 2010Publication date: May 5, 2011Inventors: Kevin R. Lynch, Timothy L. Macdonald, Yugesh Kharel, Thomas P. Mathews, Brian R. Wamhoff
-
Publication number: 20110082109Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: AJINOMOTO CO., INC.Inventors: Wataru MIYANAGA, Yoichiro Shima, Misato Noguchi, Akiko Oonuki, Yayoi Kawato, Hiroshi Iwata, Eri Harada, Ryuta Takashita, Hirokazu Ueno, Tadakiyo Nakagawa
-
Publication number: 20110077408Abstract: An organic dye used in a dye-sensitized solar cell is described, having general formula (1): D-Sp1-Ch-Sp2-Acc-Y??(1) wherein the groups D, Ch, Acc and Y are conjugate with each other, the group D is a donor group, the group Ch is a chromophore rendering low HOMO-LUMO gap or a polyaromatic chromophore, the group Acc is an acceptor group, the group Y is an anchoring group, and each of Sp1 and Sp2 represents a single bond or a spacer group allowing conjugation between the groups D and Ch or between the groups Ch and Acc.Type: ApplicationFiled: December 2, 2010Publication date: March 31, 2011Applicant: CTCI FOUNDATIONInventors: Marappan Velusamy, Koilpitchai R. Justin Thomas, Jiann T'suen Lin, Kuo-Chuan Ho, Ying-Chan Hsu
-
Patent number: 7910748Abstract: An organic electroluminescent device with a pair of electrodes having an anode and a cathode, and one or more organic compound layers disposed therebetween. One of the anode or the cathode is transparent or semitransparent.Type: GrantFiled: November 27, 2009Date of Patent: March 22, 2011Assignee: Fuji Xerox Co., Ltd.Inventors: Yoshihiro Ohba, Kazuaki Sato, Mieko Seki, Hidekazu Hirose, Takeshi Agata, Koji Horiba, Akira Imai, Tadayoshi Ozaki, Yohei Nishino, Hirohito Yoneyama, Daisuke Okuda, Toru Ishii, Kiyokazu Mashimo, Katsuhiro Sato
-
Patent number: 7902382Abstract: A thiophene-containing compound polymer represented by Y represents a bivalent hydrocarbon group; R5 represents a hydrogen atom; Z represents a bivalent hydrocarbon group; m represents 1; p represents an integer of 5 to 5,000; B and B? each represent OCH2CH2OH, and A represents a group represented by the following formula (X-III): Ar1 is a substituted or unsubstituted monovalent aromatic group; R1 to R3 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; and n representing an integer of 1 to 5.Type: GrantFiled: November 27, 2009Date of Patent: March 8, 2011Assignee: Fuji Xerox Co., Ltd.Inventors: Yoshihiro Ohba, Kazuaki Sato, Mieko Seki, Hidekazu Hirose, Takeshi Agata, Koji Horiba, Akira Imai, Tadayoshi Ozaki, Yohei Nishino, Hirohito Yoneyama, Daisuke Okuda, Toru Ishii, Kiyokazu Mashimo, Katsuhiro Sato
-
Patent number: 7893281Abstract: The invention relates to a process for preparing enantiomerically enriched aryl-aminopropanols and to their use and also to intermediates.Type: GrantFiled: July 28, 2009Date of Patent: February 22, 2011Assignee: Lanxess Deutschland GmbHInventors: Markus Eckert, Claus Dreisbach, Boris Bosch, Andreas Stolle
-
Patent number: 7893282Abstract: 7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.Type: GrantFiled: October 10, 2007Date of Patent: February 22, 2011Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Laura Honeyman
-
Publication number: 20110034528Abstract: The present invention describes Elansolids, a new class of novel anti-bacterial compounds of formula (I).Type: ApplicationFiled: February 19, 2009Publication date: February 10, 2011Inventors: Klaus Gerth, Heinrich Steinmetz, Gerhard Höfle
-
Publication number: 20110028509Abstract: The invention relates to compounds of formula I wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 16, for the treatment of CXCR3 related diseases.Type: ApplicationFiled: April 8, 2009Publication date: February 3, 2011Applicant: MERCK SERONO SAInventors: Stefano Crosignani, Christophe Cleva, Christos Tsaklakidis, Lars Burgdorf
-
Patent number: 7868205Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: September 24, 2004Date of Patent: January 11, 2011Assignee: MethylGene Inc.Inventors: Oscar Moradei, Isabelle Paquin, Silvana Leit, Sylvie Frechette, Arkadii Vaisburg, Jeffrey M. Besterman, Pierre Tessier, Tammy C. Mallais
-
Patent number: 7868189Abstract: An organic dye used in a dye-sensitized solar cell is described, having general formula (1): D-Sp1-Ch-Sp2-Acc-Y??(1) wherein the groups D, Ch, Acc and Y are conjugate with each other, the group D is a donor group, the group Ch is a chromophore rendering low HOMO-LUMO gap or a polyaromatic chromophore, the group Acc is an acceptor group, the group Y is an anchoring group, and each of Sp1 and Sp2 represents a single bond or a spacer group allowing conjugation between the groups D and Ch or between the groups Ch and Acc.Type: GrantFiled: September 24, 2008Date of Patent: January 11, 2011Assignee: CTCI FoundationInventors: Koilpitchai R. Justin Thomas, Jiann T'suen Lin, Kuo-Chuan Ho, Ying-Chan Hsu
-
Publication number: 20100331549Abstract: There is described compounds of Formulæ I, II, III, IV and V. The compounds of Formulæ I, II, III, IV and/or V are useful: in therapeutic methods and compositions for modulating cell proliferation, in diagnostic assays and as research tools.Type: ApplicationFiled: August 26, 2010Publication date: December 30, 2010Inventors: Chaim Roifman, Peter Demin, Olga Rounova, Tom Grunberger
-
Publication number: 20100324046Abstract: The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: ApplicationFiled: June 24, 2008Publication date: December 23, 2010Inventors: Paul Harrington, Richard W. Heidebrecht, JR., Solomon Kattar, Thomas A. Miller, Karin M. Otte, Phieng Siliphaivanh, Paul Tempest, Kevin J. Wilson, David J. Witter
-
Publication number: 20100317854Abstract: The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.Type: ApplicationFiled: August 23, 2010Publication date: December 16, 2010Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Cristina Alonso-Alija, Markus Heil, Dietmar Flubacher, Paul Naab, Josef Pernerstorfer, Johannes-Peter Stasch, Frank Wunder, Klaus Dembowsky, Elizabeth Perzborn, Elke Stahl
-
Publication number: 20100311794Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.Type: ApplicationFiled: June 7, 2010Publication date: December 9, 2010Applicant: Gilead Sciences, Inc.Inventor: Chandrasekar Venkataramani
-
Publication number: 20100298402Abstract: Described are novel compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These novel compounds can inhibit pSTAT3/IL-6 and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.Type: ApplicationFiled: November 4, 2008Publication date: November 25, 2010Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Sridharan Rajagopal, Thangapazham Selvakumar, Kuppusamy Bharathimohan, Virendra Kachhadia, Sriram Rajagopal, Rajendran Praveen, Ramachandran Balaji
-
Patent number: 7834013Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.Type: GrantFiled: November 15, 2004Date of Patent: November 16, 2010Assignee: GlaxoSmithKline LLCInventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, Jr.
-
Publication number: 20100267780Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.Type: ApplicationFiled: September 8, 2008Publication date: October 21, 2010Inventors: Jason Bloxham, Stuart Edward Bradley, Thomas Martin Krulle, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth
-
Publication number: 20100261910Abstract: The present invention relates to a process for the regioselective synthesis of compounds of the formula (I), wherein R1; R2; R3; R4; R5; J and W have the meanings indicated in the claims. The present invention provides an efficient and general palladium-catalyzed coupling process for aryl tosylates with terminal alkynes to a wide variety of substituted, multifunctional aryl-1-alkynes of the formula I.Type: ApplicationFiled: December 23, 2009Publication date: October 14, 2010Applicant: sanofi-aventisInventors: Omar RKYEK, Marc NAZARE, Andreas LINDENSCHMIDT, Matthias URMANN, Nis HALLAND, Jorge ALONSO
-
Publication number: 20100256156Abstract: The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R4 is a hydrogen atom and the like; R5 and R6 are each independently a hydrogen atom and the like; R1 is an optionally substituted hydrocarbon group and the like; R2 is a hydrogen atom and the like; and R3 is —(CH2)3—COOH and the like, or a salt thereof.Type: ApplicationFiled: October 31, 2008Publication date: October 7, 2010Inventors: Yoshihiro Banno, Ryoma Hara, Ryosuke Tokunoh
-
Publication number: 20100249123Abstract: The present invention provides new compounds of formula I, wherein Q, R1, R2, R4, R5, R6, Xi, R7, R8, M and G1n are defined as in formula I; invention compounds are modulators of follicle-stimulating hormone—(“FSH”) which are useful for male and female contraception as well as other disorders modulated by FSH receptor.Type: ApplicationFiled: March 19, 2008Publication date: September 30, 2010Applicant: ADDEX PHARMA SAInventors: Beatrice Bonnet, Brice Campo, Luca Raveglia, Mauro Riccaboni
-
Publication number: 20100247468Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.Type: ApplicationFiled: September 21, 2009Publication date: September 30, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Laurence Clary, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel
-
Publication number: 20100249139Abstract: The present invention relates to compounds of formula I wherein R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.Type: ApplicationFiled: March 19, 2010Publication date: September 30, 2010Inventors: Daniel Hunziker, Christian Lerner, Werner Mueller, Ulrike Obst Sander, Philippe Pflieger, Pius Waldmeier
-
Publication number: 20100240678Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification.Type: ApplicationFiled: March 10, 2010Publication date: September 23, 2010Inventors: Romyr Dominique, Robert Alan Goodnow, JR., Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
-
Patent number: 7795315Abstract: The present invention provides novel compounds of the general formula (I) and pharmaceutically acceptable salts thereof, processes for the manufacture of these novel compounds and medicaments containing such compounds. The compounds of the present invention show anti-proliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion. The invention also covers the use of such compounds for the treatment of diseases such as cancer and for the manufacture of corresponding medicaments.Type: GrantFiled: January 23, 2009Date of Patent: September 14, 2010Assignee: Hoffman-La Roche Inc.Inventors: Li Chen, Yun He, Jason Christopher Wong
-
Publication number: 20100222389Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1 are suitable for use as microbiocides.Type: ApplicationFiled: June 13, 2008Publication date: September 2, 2010Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Harald Walter, Daniel Stierli, Hans Tobler
-
Publication number: 20100216837Abstract: The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.Type: ApplicationFiled: December 21, 2005Publication date: August 26, 2010Applicant: GLAXO GROUP LIMITEDInventors: Andrea Bozzoli, Daniel Marcus Bradley, Steven Coulton, Martin Leonard Gilpin, Jacqueline Anne MacRitchie, Roderick Alan Porter, Kevin Michael Thewlis
-
Publication number: 20100210693Abstract: The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.Type: ApplicationFiled: May 3, 2010Publication date: August 19, 2010Inventors: Philippe G. Nantermet, Hemaka Anthony Rajapakse, Harold G. Selnick
-
Patent number: 7776922Abstract: The invention relates to substituted [(phenylethanoyl)amino]benzamides and methods for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of inflammatory disorders such as, for example, cutaneous, respiratory tract and cardiovascular disorders such as, for example, arteriosclerosis and coronary heart disease.Type: GrantFiled: November 17, 2005Date of Patent: August 17, 2010Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Ulf Brüggemeier, Petros Gatsios, Mark Meininghaus, Leila Telan, Elisabeth Woltering, Martina Wuttke, Hartmut Beck, Nils Griebenow, Frank Süβmeier, Niels Svenstrup, Axel Kretschmer, Marcus Bauser, Johannes Köbberling, Wahed Moradi, Siegfried Zaiss, Claudia Hirth-Dietrich, Barbara Albrecht
-
Publication number: 20100190766Abstract: Antibacterial compounds of formula (I) are provided: as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.Type: ApplicationFiled: December 10, 2009Publication date: July 29, 2010Applicant: Achaogen, Inc.Inventors: Heinz E. Moser, Qing Lu, Phillip A. Patten, Dan Wang, Ramesh Kasar, Stephen Kaldor, Brian D. Patterson
-
Publication number: 20100184768Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: ApplicationFiled: November 12, 2009Publication date: July 22, 2010Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Publication number: 20100179168Abstract: The present invention therefore provides compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.Type: ApplicationFiled: April 13, 2007Publication date: July 15, 2010Inventors: Emma Louise Blaney, David Kenneth Dean, Alessandra Gaiba, Nigel Paul King, Jason Witherington
-
Publication number: 20100173955Abstract: Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.Type: ApplicationFiled: August 21, 2007Publication date: July 8, 2010Applicant: ARRAY BIOPHARMA INC.Inventors: George Doherty, Adam Cook
-
Publication number: 20100168070Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.Type: ApplicationFiled: August 8, 2006Publication date: July 1, 2010Inventors: Niklas Heine, Klaus Fuchs, Christian Eickmeier, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
-
Patent number: 7741323Abstract: An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, R1 is C1-6 alkyl, C1-6 alkenyl, or C3-6 cycloalkyl, each of which is unsubstituted or substituted with one or more phenyl groups; R2 is H, CN, CO2Ra, CH2CO2Ra, CONRbRc, or phenyl; R3 is C1-6 alkyl, C3-6 cycloalkyl, naphthyl, phenyl, being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH2, NO2, ORa, phenyloxy, C1-6 alkyl, and C3-6 cycloalkyl; and R4, R5, R6, and R7 are each independently H, OH, OSO2CH3, O(CH2)mRe, CH2Rf, OCOCH2ORg, OCH2CH2ORg, OCH2CH?CHRg, or pyridine-2-yloxy, or R5 and R6 together form OCH2O.Type: GrantFiled: April 13, 2005Date of Patent: June 22, 2010Assignees: Korea Research Institute of Chemical Technology, Jeil Pharm. Co., Ltd., Korea Research Institute of Bioscience and Biotechnology, CJ Corp.Inventors: Hyae Gyeong Cheon, Sung-Eun Yoo, Sung Soo Kim, Sung-Don Yang, Kwang-Rok Kim, Sang Dal Rhee, Jin Hee Ahn, Seung Kyu Kang, Won Hoon Jung, Sung Dae Park, Nam Gee Kim, Jang Hyuk Lee, Sun Chul Huh, Jae Mok Lee, Seog Beom Song, Soon Ji Kwon, Jong Hoon Kim, Jeong-Hyung Lee, Seung Jun Kim
-
Publication number: 20100152098Abstract: Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.Type: ApplicationFiled: November 5, 2009Publication date: June 17, 2010Applicant: Mpex Pharmaceuticals, Inc.Inventors: Tomasz Glinka, Olga Rodny, Keith A. Bostian, David M. Wallace, Robert I. Higuchi, Chun Chow, Chi Ching Mak, Gavin Hirst, Brian Eastman
-
Publication number: 20100152188Abstract: The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their stereoisomers, their pharmaceutically acceptable salts and compositions. The present invention more particularly provides novel heterocyclic compounds of the general formula (I).Type: ApplicationFiled: August 4, 2006Publication date: June 17, 2010Inventors: Akella Satya Surya Visweswara Srinivas, Kasinathan Mathiyazhagan, Duddu Savaraiah Sharada, Thanasekaran Ponpandian, Kulasekharan Revathy, Gaddam Om Reddy, Mani Kamarai, Sriram Raiagopal
-
Publication number: 20100144681Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.Type: ApplicationFiled: August 8, 2006Publication date: June 10, 2010Inventors: Klaus Fuchs, Christian Eickmeier, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
-
Publication number: 20100137402Abstract: The subject of the present invention is compounds corresponding to formula (I): Wherein X, R1, R2, R3 and R4 are as described herein. The invention also relates to a method for the preparation and application of said compounds as cannabinoid CB1 receptor antagonists.Type: ApplicationFiled: February 8, 2010Publication date: June 3, 2010Applicant: SANOFI-AVENTISInventors: Jean-Philippe DUCOUX, Francis BARTH, Murielle RINALDI-CARMONA, Christian CONGY
-
Publication number: 20100126563Abstract: Dyes for dye-sensitized solar cell are provided. Each of the dyes for a dye-sensitized solar cell according to an embodiment has a chemical structure: wherein each of X and Y may comprise a substituent, comprising aromatic hydrocarbon groups which are respectively independently substituted or unsubstituted, aromatic heterocyclic groups which are substituted or unsubstituted, and a combination thereof, Z may comprise aromatic hydrocarbon groups which are substituted or unsubstituted, heterocyclic groups which are substituted or unsubstituted, vinyl groups, and polyvinyl groups which are substituted or unsubstituted, and A may comprise acid functional groups.Type: ApplicationFiled: September 16, 2009Publication date: May 27, 2010Inventors: Jonghyun Park, Seongkee Park, Sunghoon Joo, Jinok Hwang, Taeyoun Kim
-
Publication number: 20100122729Abstract: The present invention relates to a dye compound represented by the following formula (I), or a salt thereof: wherein R1, R2, R3, R4, D1, D2, B, and n are defined the same as the specification, and also relates to a photoelectric component using the same. The dye compound of the present invention is suitable for Dye-Sensitized Solar Cell (DSSC). Hence, the photoelectric characteristics of the DSSC can be improved by using the dye compound of the present invention.Type: ApplicationFiled: January 22, 2009Publication date: May 20, 2010Applicant: Everlight USA, Inc.Inventors: Ming-Si Wu, Wei-Cheng Tang
-
Patent number: 7713961Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1—X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.Type: GrantFiled: March 30, 2006Date of Patent: May 11, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Christian Eickmeier, Stefan Peters, Klaus Fuchs, Niklas Heine, Sandra Handschuh, Cornelia Dorner-Ciossek, Klaus Klinder, Marcus Kostka
-
Publication number: 20100105900Abstract: A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 9, 2008Publication date: April 29, 2010Inventors: Heinz W. Pauls, Peter Brent Sampson, Bryan T. Forrest, Radoslaw Laufer, Yong Liu, Miklos Feher, Yi Yao, Guohua Pan
-
Publication number: 20100093828Abstract: Disclosed are compounds of formula (IA), formula (IV) or formula (V), and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.Type: ApplicationFiled: August 20, 2007Publication date: April 15, 2010Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Jun Jiang
-
Publication number: 20100076205Abstract: A dye compound is described, which is expressed by formula (I): wherein A1, A2 and A3 each independently represent a substituted or unsubstituted 1,4-phenylene or 2,5-thiophene group, and B1 and B2 each independently represent a substituted or unsubstituted aryl group. The dye compound is suitably used as a dye sensitizer in a dye sensitized solar cell (DSSC).Type: ApplicationFiled: May 19, 2009Publication date: March 25, 2010Applicant: Academia SinicaInventors: Tahsin J. Chow, Yuan-Chieh Chang
-
Patent number: 7674821Abstract: The invention concerns compounds of formula (I), wherein X, R1, R2, R3, R4 and R5 are as defined herein. The invention also concerns a method for preparing said compounds and their use as cannabinoid CB1 receptor antagonists.Type: GrantFiled: June 18, 2007Date of Patent: March 9, 2010Assignee: Sanofi-AventisInventors: Francis Barth, Christian Congy, Jean-Phillipe Ducoux, Murielle Rinaldi-Carmona
-
Patent number: 7659410Abstract: Provided are a thiophene-containing compound represented by the following formula (X-1), and an organic electroluminescent device that includes a pair of electrodes and an organic compound layer disposed therebetween. The organic compound layer includes a charge-transporting polyester having a repeating structure containing at least one structure selected from the structures represented by the following formulae (I-1) and (I-2) as its partial structure. In formula (X-1), Ar1 represents a substituted or unsubstituted monovalent aromatic group; and R1 to R4 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; and n? is an integer of 1 to 5.Type: GrantFiled: December 12, 2006Date of Patent: February 9, 2010Assignee: Fuji Xerox Co., Ltd.Inventors: Yoshihiro Ohba, Kazuaki Sato, Mieko Seki, Hidekazu Hirose, Takeshi Agata, Koji Horiba, Akira Imai, Tadayoshi Ozaki, Yohei Nishino, Hirohito Yoneyama, Daisuke Okuda, Toru Ishii, Kiyokazu Mashimo, Katsuhiro Sato
-
Publication number: 20100029670Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: ApplicationFiled: July 30, 2009Publication date: February 4, 2010Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson